Navigation Links
New Research Released at AHA Confirms Itamar's PAT Technology to Diagnose Early Cardiovascular Disease
Date:11/4/2007

Four presentations at AHA, including one from the Framingham Heart Study, link PAT signal with several cardio-vascular conditions and risk factors as

technology gains broader acceptance

ORLANDO, Fla., Nov. 4 /PRNewswire/ -- Itamar Medical announced confirmation of PAT technology by several prestigious research groups. In light of scientific confirmation of PAT technology, Itamar Medical will now promote clinical use in the medical community for the prevention of cardiovascular disease.

Presentation of several research works at the American Heart Association's Scientific Sessions, including one by the Framingham Heart Study, as well as numerous other recently published studies, support the emerging of the Endo- PAT as a significant tool in the prevention and management of cardiovascular disease.

Based on the new studies, combined with earlier numerous successful trials of the Endo-PAT at the Mayo Clinic, Harvard University and other academic medical centers, Itamar Medical is now ready to make Endo-PAT Technology available to clinicians beyond the research environment and into the general medical community.

The Endo-PAT, developed by Itamar Medical, is the only FDA approved non- invasive device that reliably detects a pathology called endothelial dysfunction. The condition refers to an impairment of the endothelial layer, which is the inner tissue lining of the blood vessels and is emerging as a key precursor for the development of atherosclerosis -- a major component in cardiac disease, the nation's number one killer.

The non-invasive Endo-PAT device, based on PAT technology, measures subtle but significant vaso-motion changes through a small thimble-like probe placed over a person's index finger. Tests administered with the Endo-PAT provide clinicians and researchers an effective tool for the detection of endothelial dysfunction. Early detection has the potential to reduce the medical and cost burden of cardiovascular disease. Valuable diagnostic information can be obtained from the Endo-PAT at a fraction of the cost of other established approaches which can only be administered by a skilled technician and even then are too operator dependent.

In addition to the data from the Framingham Heart Study, that showed in a large population base study an association between the Endo-PAT results and several risk factors, three other oral presentations from Britain and Sweden showed the relevancy of endothelial function assessment with the Endo-PAT in other conditions in children and adults.

About Itamar Medical

Itamar Medical Ltd., established in 1997, is a public (TASE: ITMR) medical technology company that developed the proprietary PAT(TM) (Peripheral Arterial Tone) signal technology and applications. The PAT signal is a non-invasive "window" to the cardiovascular system and the autonomic nervous system. For more information, visit http://www.itamar-medical.com


'/>"/>
SOURCE Itamar Medical Ltd.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Kidney Stones - Interesting New Research implicates bacteria as its cause
2. Stem cell research- now Nobel Laureates join the debate
3. Researchers urge caution in using ear tube surgery
4. Paracetamol May Cause Live Damage Warns Consumer Education and Research Centre
5. Spouses and other partners lower blood pressure says new research
6. Researchers Scale to assess the Severity of Epilepsy in Kids
7. More Research Required For COPD
8. Researchers identify the early makers of Neonatal Sepsis
9. OHSU Researchers Announce New Discovery
10. Skin Cancer Research To Go Global
11. Researchers Identify Gene Connected To Bipolar Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... ... January 16, 2017 , ... ... teacher, http://www.ageofautism.com/legal , Sharon Kleyne, America’s leading water educator, researcher and ... nationally syndicated radio program, The Sharon Kleyne Hour Power of Water, Global Climate ...
(Date:1/16/2017)... , ... January 16, 2017 , ... ... to provide first-quality education and high-level training standards to an international multidisciplinary group ... eating disorder problems. As a way to further its mission at the grassroots ...
(Date:1/16/2017)... ... January 16, 2017 , ... San Francisco dentist, Dr. ... latest in 3-D scanning device which is capable of taking digital impressions of teeth ... dentistry, such as CAD CAM restorations , in terms of speed, efficiency and ...
(Date:1/16/2017)... ... January 16, 2017 , ... NexTec Group has been selected ... 100 organizations honored for their accomplishments in the field of midmarket financial software. , ... and recognition, and innovation. Selection is not based on revenue and those firms chosen ...
(Date:1/15/2017)... ... 15, 2017 , ... Going above and beyond the practical ... better communities around the world by offering the Gensuite team and their services ... team members to become involved in a cause that is bigger than themselves ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... , January 17, 2017 ... 2016;11(Suppl. 1):2-4 ; http://www.touchneurology.com/articles/tailored-temperature-management-neurocritical-care ... ... Published recently in European Neurological ... touchNEUROLOGY, Catherine Amey reports that despite ...
(Date:1/17/2017)... -- Transparency Market Research has released a new market ... Alcohol and Others) Market - Global Industry Analysis, Size, Share, Growth, ... benzaldehyde derivative market was valued at US$ 1.37 Bn in ... expanding at a CAGR of 5.1 % from 2016 to 2024. ... Benzaldehyde derivatives are ...
(Date:1/17/2017)... BUDAPEST, Hungary , Jan. 17, 2017 /PRNewswire/ ... Plc. today announced positive results from Venus II, the second ... and safety of ulipristal acetate in women with abnormal bleeding ... ulipristal acetate is planned for the second half of 2017. ... Venus II supporting the efficacy and safety profile of ulipristal ...
Breaking Medicine Technology: